Summary
Global Markets Direct’s, ‘Salivary Gland Cancer - Pipeline Review, H1 2016’, provides an overview of the Salivary Gland Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Salivary Gland Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Salivary Gland Cancer and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Salivary Gland Cancer
- The report reviews pipeline therapeutics for Salivary Gland Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Salivary Gland Cancer therapeutics and enlists all their major and minor projects
- The report assesses Salivary Gland Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Salivary Gland Cancer
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Salivary Gland Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Salivary Gland Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Bayer AG
Ignyta, Inc.
Loxo Oncology, Inc.
Otsuka Holdings Co., Ltd.
Plexxikon Inc.
Taiwan Liposome Company, Ltd.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Salivary Gland Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Salivary Gland Cancer - Overview 7
Pipeline Products for Salivary Gland Cancer - Comparative Analysis 8
Salivary Gland Cancer - Therapeutics under Development by Companies 9
Salivary Gland Cancer - Therapeutics under Investigation by Universities/Institutes 10
Salivary Gland Cancer - Pipeline Products Glance 11
Clinical Stage Products 11
Salivary Gland Cancer - Products under Development by Companies 12
Salivary Gland Cancer - Products under Investigation by Universities/Institutes 13
Salivary Gland Cancer - Companies Involved in Therapeutics Development 14
Bayer AG 14
Ignyta, Inc. 15
Loxo Oncology, Inc. 16
Otsuka Holdings Co., Ltd. 17
Plexxikon Inc. 18
Taiwan Liposome Company, Ltd. 19
Salivary Gland Cancer - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
Cellular Immunotherapy for Oncology - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
entrectinib - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
LOXO-101 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
OPB-111001 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
pexidartinib - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
regorafenib - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
TLC-388 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Salivary Gland Cancer - Recent Pipeline Updates 44
Salivary Gland Cancer - Dormant Projects 61
Salivary Gland Cancer - Discontinued Products 62
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64
List of Tables
Number of Products under Development for Salivary Gland Cancer, H1 2016 7
Number of Products under Development for Salivary Gland Cancer - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Products under Investigation by Universities/Institutes, H1 2016 13
Salivary Gland Cancer - Pipeline by Bayer AG, H1 2016 14
Salivary Gland Cancer - Pipeline by Ignyta, Inc., H1 2016 15
Salivary Gland Cancer - Pipeline by Loxo Oncology, Inc., H1 2016 16
Salivary Gland Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 17
Salivary Gland Cancer - Pipeline by Plexxikon Inc., H1 2016 18
Salivary Gland Cancer - Pipeline by Taiwan Liposome Company, Ltd., H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 26
Number of Products by Stage and Molecule Type, H1 2016 28
Salivary Gland Cancer Therapeutics - Recent Pipeline Updates, H1 2016 44
Salivary Gland Cancer - Dormant Projects, H1 2016 61
Salivary Gland Cancer - Discontinued Products, H1 2016 62
List of Figures
Number of Products under Development for Salivary Gland Cancer, H1 2016 7
Number of Products under Development for Salivary Gland Cancer - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 11
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Top 10 Targets, H1 2016 21
Number of Products by Stage and Top 10 Targets, H1 2016 21
Number of Products by Top 10 Mechanism of Actions, H1 2016 23
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 23
Number of Products by Routes of Administration, H1 2016 25
Number of Products by Stage and Routes of Administration, H1 2016 25
Number of Products by Molecule Types, H1 2016 27
Number of Products by Stage and Molecule Types, H1 2016 27
